Clinical Trial: Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment

U.S., April 18 -- ClinicalTrials.gov registry received information related to the study (NCT06932471) titled 'Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment' on April 09.

Brief Summary: The main purpose of this study is to evaluate the efficacy of MY008211A in PNH patients with residual anemia despite treatment with anti-C5 antibody.

Study Start Date: Aug. 30, 2024

Study Type: INTERVENTIONAL

Condition: Paroxysmal Nocturnal Hemoglobinuria (PNH) With Signs of Active Hemolysis

Intervention: DRUG: MY008211A tablets

MY008211A tablets Participants will receive MY008211A at a dose of 400 mg orally b.i.d

Recruitment Status: RECRUITING

Sponsor: Wuhan Createrna Science and Techn...